SHARPE
Reported results
- Total revenues were $226.8 million in the third quarter of 2026, an 18% increase compared to $192.1 million in the third quarter of 2025.
- GAAP Net product sales were $178.6 million in the third quarter of 2026 compared to $168.5 million in the third quarter of 2025.
- Non-GAAP total revenues from commercial products were $220.3 million in the third quarter of 2026 compared to $188.7 million in the third quarter of 2025.
- Operating earnings (loss) - GAAP was an earnings of $21.2 million for the third quarter of 2026, compared to an operating loss of $60.2 million in the third quarter of 2025.
- Adjusted operating earnings (non-GAAP) were $55.2 million for the third quarter of 2026 compared to $41.9 million for the third quarter of 2025.
- Net earnings were $20.9 million, or $0.35 per diluted share, for the third quarter of 2026, compared to a net loss of $45.1 million, or $0.80 per diluted share, for the third quarter of 2025.
Guidance
- Full year 2026 total revenues guidance raised to $875 million - $900 million.
- Full year 2026 Operating Earnings (Loss) - GAAP guidance raised to $(5) million - $(40) million.
- Full year 2026 Operating Earnings - As Adjusted (Non-GAAP) guidance raised to $160 million - $180 million.
- Full year 2026 ONAPGO net sales expected to be $60 million - $65 million.
- Full year 2026 Trokendi XR and Oxtellar XR net sales expected to be $60 million - $67 million.
Notes
Supernus entered into an agreement for an all-stock merger with Indivior Pharmaceuticals, Inc., expected to close on November 2, 2026, after which stand-alone guidance will no longer apply.
Price and volatility reaction
The stock moved +0.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -1.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 27.3508 | 2026-10-29 |
| Close after release | 27.4439 | 2026-10-30 |
| Realised move | +0.3% | close to close |
| 30d ATM IV change | -1.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.